Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies

Critical Care Medicine

Volumn 40, Issue 2, 2012, Pages 634-646

  Landoni, Giovanni ^a   Biondi Zoccai, Giuseppe ^b   Greco, Massimiliano ^a   Greco, Teresa ^a   Bignami, Elena ^a   Morelli, Andrea ^c   Guarracino, Fabio ^d   Zangrillo, Alberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

anesthesia; cardiac surgery; heart failure; inotropic support; intensive care; levosimendan; mortality; survival

Indexed keywords

DOBUTAMINE; ENOXIMONE; LEVOSIMENDAN; MILRINONE; PLACEBO; PROSTAGLANDIN E1;

CONTINUOUS INFUSION; DRUG EFFECT; FOLLOW UP; HEART FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HEART SURGERY; HOSPITALIZATION; HUMAN; HYPOTENSION; LENGTH OF STAY; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION;

CARDIAC SURGICAL PROCEDURES; CRITICAL ILLNESS; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; HYDRAZONES; INTENSIVE CARE; PROGNOSIS; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84856185198     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318232962a     Document Type: Review

References (120)

1. Bayram M, De Luca L, Massie MB, et al: Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 2005; 96:47G-58G
2. Thackray S, Easthaugh J, Freemantle N, et al: The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 2002; 4:515-529
3. Metra M, Eichhorn E, Abraham WT, et al: Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: The randomized, doubleblind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J 2009; 30: 3015-3026
4. Abraham WT, Adams KF, Fonarow GC, et al: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46:57-64
5. Mebazaa A, Parissis J, Porcher R, et al: Short-term survival by treatment among patients hospitalized with acute heart failure: The global ALARM-HF registry using propensity scoring methods. Intensive Care Med 2011; 37:290-301
6. Despas F, Trouillet C, Franchitto N, et al: Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: Direct evidence from sympathetic neural recording. Acute Card Care 2010; 12:25-30
7. Papp Z, Csapó K, Pollesello P, et al: Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev 2005; 23:71-98
8. Follath F, Cleland JG, Just H, et al: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe lowoutput heart failure (the LIDO study): A randomised double-blind trial. Lancet 2002; 360:196-202
9. Moiseyev VS, Põder P, Andrejevs N, et al: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebocontrolled, double-blind study (RUSSLAN). Eur Heart J 2002; 23:1422-1432
10. Zairis MN, Apostolatos C, Anastasiadis P, et al: The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: Results from the calcium sensitizer or inotrope or none in low output heart failure study (CASINO). J Am Coll Cardiol 2004; 43:A206-A207
11. Mebazaa A, Nieminen MS, Packer M, et al: Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. JAMA 2007; 297:1883-1891
12. Packer M, Revive II Trial Investigators: REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Circulation 2005; 112:3363
13. Landoni G, Mizzi A, Biondi-Zoccai G, et al: Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies. Minerva Anestesiol 2010; 76:276-286
14. Delaney A, Bradford C, McCaffrey J, et al: Levosimendan for the treatment of acute severe heart failure: A meta-analysis of randomised controlled trials. Int J Cardiol 2010; 138:281-289
15. Mebazaa A, Nieminen MS, Filippatos GS, et al: Levosimendan vs. dobutamine: Outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 2009; 11:304-311
16. Cohen-Solal A, Logeart D, Huang B, et al: Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol 2009; 53:2343-2348
17. Cleland JG, Freemantle N, Coletta AP, et al: Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006; 8:105-110
18. Gheorghiade M, Pang PS: Are BNP changes during hospitalization for heart failure a reliable surrogate for predicting the effects of therapies on post-discharge mortality? J Am Coll Cardiol 2009; 53:2349-2352
19. Nieminen MS: Levosimendan compared with dobutamine in low output patients. Minerva Anestesiol 2003; 69:258-263
20. Cleland JG, Takala A, Apajasalo M, et al: Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: An analysis based on the international LIDO trial. Eur J Heart Fail 2003; 5:101-108
21. Cleland JG, Ghosh J, Freemantle N, et al: Clinical trials update and cumulative metaanalyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004; 6:501-508
22. Coletta AP, Cleland JG, Freemantle N, et al: Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and metaanalysis of cardiac resynchronisation therapy. Eur J Heart Fail 2004; 6:673-676
23. Packer M, Colucci WS, Fisher L, et al: Development of a comprehensive new end point for the evaluation of new treatments for acute decompensated heart failure (results with levosimendan in the REVIVE-1 study). Abstr. J Card Fail 2003; 9:S61
24. Kota B, Prasad AS, Economides C, et al: Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: Impact on heart failure. J Cardiovasc Pharmacol Ther 2008; 13:269-278
25. de Lissovoy G, Fraeman K, Teerlink JR, et al: Hospital costs for treatment of acute heart failure: Economic analysis of the REVIVE II study. Eur J Health Econ 2010; 11:185-193
26. Biondi-Zoccai GG, Agostoni P, Abbate A, et al: A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol 2005; 34:224-225; author reply 225
27. Higgins JPT, Green S: Cochrane handbook for systematic reviews of interventions (v 5.0.2). Available at: http://www.cochranehandbook. org. Accessed January 4, 2011
28. Peters JL, Sutton AJ, Jones DR, et al: Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006; 295: 676-680
29. Dear KBG, Begg CB: An approach for assessing publication bias prior to performing a meta-analysis. Statistical Science 1992; 7:237-245
30. Duval S, Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in metaanalysis. Biometrics 2000; 56:455-463
31. Review manager (RevMan) [computer program] version 5.0. Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration, 2008. Available at: http://ims.cochrane. org/revman. Accessed January 4, 2011
32. Liberati A, Altman DG, Tetzlaff J, et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009; 339:b2700
33. Akselrod B, Trekova N, Tolstova I, et al: Preoperative levosimendan administration: What is the vascular payment during anaes-thesia? J Cardiothorac Vasc Anesth 2010; 24:S18
34. Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, et al: The Ca2 -sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005; 7:882-887
35. Chamos C, Daidou T, Delis E, et al: The effects of levosimendan compared with milrinone in cardiac surgery patients. J Cardiothorac Vasc Anesth 2009; 23:S19
36. De Luca L, Proietti P, Celotto A, et al: Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J 2005; 150: 563-568
37. De Luca L, Sardella G, Proietti P, et al: Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: A Doppler echocardiographic study. J Am Soc Echocardiogr 2006; 19:172-177
38. Duman D, Palit F, Simsek E, et al: Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure. Can J Cardiol 2009; 25:e353-e356
39. Duygu H, Nalbantgil S, Zoghi M, et al: Comparison of ischemic side effects of levosimendan and dobutamine with integrated backscatter analysis. Clin Cardiol 2009; 32: 187-192
40. Harjola VP, Oikarinen L, Toivonen L, et al: The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure. Int J Clin Pharmacol Ther 2008; 46:389-399
41. Jörgensen K, Bech-Hanssen O, Houltz E, et al: Effects of levosimendan on left ventricular relaxation and early filling at maintained preload and afterload conditions after aortic valve replacement for aortic stenosis. Circulation 2008; 117:1075-1081
42. Kasikcioglu HA, Uyarel H, Tartan Z, et al: Do calcium sensitizers affect right ventricular functions in patients with chronic heart failure? Int J Cardiol 2007; 118: 246-248
43. Knez I, Schweiger S, Ovcina I, et al: Effects of Ca2 sensitiser levosimendan on flow in internal thoracic and radial arteries in patients undergoing CABG-preliminary results. Abstr. Eur Heart J 2005; 26:527
44. Kurt IH, Yavuzer K, Batur MK: Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure. Heart Vessels 2010; 25:392-399
45. Lilleberg J, Nieminen MS, Akkila J, et al: Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998; 19:660-668
46. Moertl D, Berger R, Huelsmann M, et al: Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. Eur J Heart Fail 2005; 7:1156-1163
47. Parissis JT, Adamopoulos S, Antoniades C, et al: Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004; 93:1309-1312
48. Parissis JT, Adamopoulos S, Farmakis D, et al: Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 2006; 92:1768-1772
49. Parissis JT, Andreadou I, Markantonis SL, et al: Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis 2007; 195:e210-e215
50. Parissis JT, Karavidas A, Bistola V, et al: Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis 2008; 197: 278-282
51. Parissis JT, Panou F, Farmakis D, et al: Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005; 96:423-426
52. Sonntag S, Sundberg S, Lehtonen LA, et al: The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004; 43:2177-2182
53. Yilmaz MB, Karadas F, Erdem A, et al: Improvement in Doppler alternans in patients with severe heart failure: Levosimendan versus dobutamin. Int J Cardiol 2008; 125: 104-106
54. Yilmaz MB, Yalta K, Yontar C, et al: Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther 2007; 21:431-435
55. Wang L, Cui L, Wei JP, et al: [Efficacy and safety of intravenous levosimendan compared with dobutamine in decompensated heart failure]. Zhonghua Xin Xue Guan Bing Za Zhi 2010; 38:527-530
56. Yilmaz MB, Yontar C, Erdem A, et al: Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure. Heart Vessels 2009; 24:16-21
57. Nieminen MS, Cleland JG, Eha J, et al: Oral levosimendan in patients with severe chronic heart failure-the PERSIST study. Eur J Heart Fail 2008; 10:1246-1254
58. Põder P, Eha J, Sundberg S, et al: Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: A dosing interval study. J Clin Pharmacol 2004; 44:1143-1150
59. Branzi G, Malfatto G, Villani A, et al: Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure. J Cardiovasc Med (Hagerstown) 2010; 11: 662-668
60. Lehmann A, Kiessling AH, Isgro F, et al: Levosimendan in patients with acute myocardial ischaemia undergoing emergency surgical revascularization. Eur J Anaesthesiol 2008; 25:224-229
61. Nanas JN, Papazoglou P, Tsagalou EP, et al: Efficacy and safety of intermittent, longterm, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol 2005; 95:768-771
62. Liu T, Li G, Xu G: Levosimendan may prevent postoperative atrial fibrillation through anti-inflammatory and antioxidant modulation. J Cardiothorac Vasc Anesth 2009; 23:757-758
63. Tasouli A, Papadopoulos K, Antoniou T, et al: Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: Importance of early use. Eur J Cardiothorac Surg 2007; 32: 629-633
64. Dominguez-Rodriguez A, Samimi-Fard S, Garcia-Gonzalez MJ, et al: Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty. Int J Cardiol 2008; 128:214-217
65. Duygu H, Nalbantgil S, Ozerkan F, et al: Effects of levosimendan on left atrial functions in patients with ischemic heart failure. Clin Cardiol 2008; 31:607-613
66. Duygu H, Ozerkan F, Zoghi M, et al: Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure. Int J Clin Pract 2008; 62:228-233
67. Kivikko M, Lehtonen L, Colucci WS: Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107:81-86
68. Samimi-Fard S, Garcia-Gonzalez MJ, Dominguez-Rodriguez A, et al: Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. Int J Cardiol 2008; 127:284-287
69. Levin RL, Degrange M, Porcile R, et al: The preoperative utilization of levosimendan (preoperative optimization) reduced mortality and low output syndrome after cardiac surgery in patients with low ejection fraction (EF-25%). Circulation 2007; 116:82
70. Momeni M, Rubay J, Matta A, et al: Levosimendan in congenital cardiac surgery: A randomized, double-blind clinical trial. J Cardiothorac Vasc Anesth 2011; 25: 419-424
71. Adamopoulos S, Parissis JT, Iliodromitis EK, et al: Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006; 98: 102-106
72. Alhashemi JA, Alotaibi QA, Abdullah GM, et al: Levosimendan vs dobutamine in septic shock. J Crit Care 2009; 24:e14-e15
73. Al-Shawaf E, Ayed A, Vislocky I, et al: Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. J Cardiothorac Vasc Anesth 2006; 20: 353-357
74. Alvarez J, Bouzada M, Fernández AL, et al: [Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery]. Rev Esp Cardiol 2006; 59:338-345
75. Alvarez J, Taboada M, Rodríguez J, et al: [Hemodynamic effects of levosimendan following cardiac surgery]. Rev Esp Anestesiol Reanim 2005; 52:389-394
76. Barisin S, Husedzinovic I, Sonicki Z, et al: Levosimendan in off-pump coronary artery bypass: A four-times masked controlled study. J Cardiovasc Pharmacol 2004; 44: 703-708
77. Berger R, Moertl D, Huelsmann M, et al: Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Eur J Heart Fail 2007; 9:202-208
78. Bergh CH, Andersson B, Dahlström U, et al: Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail 2010; 12:404-410
79. De Hert SG, Lorsomradee S, Cromheecke S, et al: The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007; 104:766-773
80. De Hert SG, Lorsomradee S, vanden Eede H, et al: A randomized trial evaluating different modalities of levosimendan administration in cardiac surgery patients with myocardial dysfunction. J Cardiothorac Vasc Anesth 2008; 22:699-705
81. Duygu H, Ozerkan F, Nalbantgil S, et al: Effect of levosimendan on E/E' ratio in patients with ischemic heart failure. Int J Cardiol 2008; 123:201-203
82. Duygu H, Turk U, Ozdogan O, et al: Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol. Cardiovasc Ther 2008; 26:182-188
83. Eriksson HI, Jalonen JR, Heikkinen LO, et al: Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg 2009; 87:448-454
84. Flevari P, Parissis JT, Leftheriotis D, et al: Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol 2006; 98:1641-1645
85. Fuhrmann JT, Schmeisser A, Schulze MR, et al: Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2008; 36:2257-2266
86. García-González MJ, Domínguez-Rodríguez A, Ferrer-Hita JJ, et al: Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail 2006; 8:723-728
87. Husedzinoviæ I, Barisin S, Bradiæ N, et al: Levosimendan as a new strategy during offpump coronary artery bypass grafting: Double-blind randomized placebo-controlled trial. Croat Med J 2005; 46:950-956
88. Ikonomidis I, Parissis JT, Paraskevaidis I, et al: Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure. Eur J Heart Fail 2007; 9:1172-1177
89. Järvelä K, Maaranen P, Sisto T, et al: Levosimendan in aortic valve surgery: Cardiac performance and recovery. J Cardiothorac Vasc Anesth 2008; 22:693-698
90. Kleber FX, Bollmann T, Borst MM, et al: Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: Results of a pilot study. J Clin Pharmacol 2009; 49:109-115
91. Lahtinen P, Pitkänen O, Pö lönen P, et al: Levosimendan reduces heart failure after high risk cardiac surgery-a prospective, randomized, placebo-controlled trial. Eur Heart J 2009; 30:596
92. Leppikangas H, Tenhunen JJ, Lindgren L, et al: Effects of levosimendan on indocyanine green plasma disappearance rate and the gastric mucosal-arterial pCO2 gradient in abdominal aortic aneurysm surgery. Acta Anaesthesiol Scand 2008; 52:785-792
93. Levin RL, Degrange MA, Del-Mazo C, et al: Superiority of levosimendan over dobutamine in low cardiac output syndrome after aortic valve replacement. Circulation 2008; 118: E231
94. Levin RL, Degrange MA, Porcile R, et al: Preoperative use of calcium sensitizer levosimendan reduces mortality and low cardiac output syndrome in patients with aortic stenosis and left ventricular dysfunction. Circulation 2008; 118:E217
95. Levin RL, Degrange MA, Porcile R, et al: [The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome]. Rev Esp Cardiol 2008; 61:471-479
96. Levin R, Porcile RT, Degrange M: The intermittent infusion of levosimendan reduces mortality and readmissions in patients with advanced heart failure. Circulation 2009; 120:s865
97. Levin R, Porcile R, Salvagio F, et al: Levosimendan reduces mortality in postoperative low cardiac output syndrome after coronary surgery. Circulation 2009; 120:S987-S988
98. Lilleberg J, Laine M, Palkama T, et al: Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 2007; 9:75-82
99. Mavrogeni S, Giamouzis G, Papadopoulou E, et al: A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail 2007; 13:556-559
100. Morelli A, De Castro S, Teboul JL, et al: Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005; 31:638-644
101. Nieminen MS, Akkila J, Hasenfuss G, et al: Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1903-1912
102. Nijhawan N, Nicolosi AC, Montgomery MW, et al: Levosimendan enhances cardiac performance after cardiopulmonary bypass: A prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999; 34:219-228
103. Parissis JT, Papadopoulos C, Nikolaou M, et al: Effects of levosimendan on quality of life and emotional stress in advanced heart failure patients. Cardiovasc Drugs Ther 2007; 21: 263-268
104. Slawsky MT, Colucci WS, Gottlieb SS, et al: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000; 102:2222-2227
105. Trikas A, Antoniades C, Latsios G, et al: Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail 2006; 8:804-809
106. Tritapepe L, De Santis V, Vitale D, et al: Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth 2009; 102:198-204
107. Tritapepe L, De Santis V, Vitale D, et al: Preconditioning effects of levosimendan in coronary artery bypass grafting-a pilot study. Br J Anaesth 2006; 96:694-700
108. Tziakas DN, Chalikias GK, Hatzinikolaou HI, et al: Levosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure. Cardiovasc Drugs Ther 2005; 19:399-402
109. Zemljic G, Bunc M, Yazdanbakhsh AP, et al: Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Card Fail 2007; 13:417-421
110. Ribeiro RA, Rohde LE, Polanczyk CA: Levosimendan in acute decompensated heart failure: Systematic review and metaanalysis. Arq Bras Cardiol 2010; 95: 230-237
111. Bonaros N, Vill D, Wiedemann D, et al: Major risk stratification models do not predict perioperative outcome after coronary artery bypass grafting in patients with previous percutaneous intervention. Eur J Cardiothorac Surg 2011; 39:e164-e169
112. Annane D, Vignon P, Renault A, et al: Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: A randomised trial. Lancet 2007; 370:676-684
113. De Backer D, Biston P, Devriendt J, et al: Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362:779-789
114. Dickstein K, Cohen-Solal A, Filippatos G, et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10:933-989
115. Follath F: Newer treatments for decompensated heart failure: Focus on levosimendan. Drug Des Devel Ther 2009; 3:73-78
116. Tavares M, Rezlan E, Vostroknoutova I, et al: New pharmacologic therapies for acute heart failure. Crit Care Med 2008; 36: S112-S120
117. Zangrillo A, Biondi-Zoccai G, Mizzi A, et al: Levosimendan reduces cardiac troponin release after cardiac surgery: A meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth 2009; 23:474-478
118. Landoni G, Mizzi A, Biondi-Zoccai G, et al: Reducing mortality in cardiac surgery with levosimendan: A meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 2010; 24:51-57
119. Hamilton MA, Cecconi M, Rhodes A: A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. Anesth Analg 2011; 112:1392-1402
120. Levosimendan in High Risk Patients Undergoing Cardiac Surgery (HSR-LEVO). ClinicalTrials.gov Identifier NCT00994825. Available at: http://www. clinicaltrials.gov. Accessed January 5, 2011